UPDATE : Thursday, October 18, 2018
상단여백
Biogen, Samsung Bioepis announce European launch of Imraldi by Lee Han-soo 2018-10-17 17:28
Bio stocks listed under ‘tech exception policy’ perform better by Nam Doo-hyun 2018-10-15 12:27
Merck to supply Samsung’s biosimilar to US Veterans Affairs Dept. by Lee Han-soo 2018-10-11 16:31
US drug advisory recommends Celltrion’s Rituxan biosimilar for approval by Lee Han-soo 2018-10-11 12:10
‘Korea publishes many biotech papers but rarely links them to biz’ by Nam Doo-hyun 2018-10-10 16:35
라인
GC opens new cell research center by Lee Han-soo 2018-10-10 11:45
More biotech stocks come in top 20 on KOSDAQ by Nam Doo-hyun 2018-10-10 11:20
Newly listed biotech firms perform poorly on KOSDAQ by Nam Doo-hyun 2018-10-04 13:09
‘Samsung C&T’s value to rise on BioLogics’ increased value’ by Nam Doo-hyun 2018-10-03 10:11
More doctoral degree holders wanted at biotech ventures by Nam Doo-hyun 2018-10-02 14:40
라인
FDA to review Samsung Bioepis’ application for anti-arthritis biosimilar by Lee Han-soo 2018-09-27 11:22
Biois registers patent to develop TNF-alpha inhibitor by So Jae-hyeon 2018-09-20 16:45
Celltrion, Emory University to develop new drug for Atherosclerosis by Lee Han-soo 2018-09-20 13:22
FDA approves Bifido’s strain as new dietary ingredient by Lee Han-soo 2018-09-18 17:14
Nature Cell shares spike despite investment alert warning by Nam Doo-hyun 2018-09-14 16:08
라인
GC Cell shares spike on winning FDA nod for Immuncell-LC by Nam Doo-hyun 2018-09-12 16:05
‘Regulator’s scrutiny into ToolGen’s patent issue might discourage biotech research’ by So Jae-hyeon 2018-09-12 14:25
‘ToolGen’s KOSDAQ listing might be in peril’ by Nam Doo-hyun 2018-09-10 14:59
‘Pharmaceutical stocks to bottom out soon’ by Nam Doo-hyun 2018-08-29 14:34
Celltrion completes P3 clinical trials for Remsima in Europe by Lee Han-soo 2018-08-29 14:33
여백
여백
여백
Back to Top